INDUSTRIAL INSTRUMENTS FOR MEASUREMENT, DISPLAY, AND CONTROL
Danaher Corporation
DHR
In 1984, Danaher's founders transformed a real estate organization into an industrial-focused manufacturing company. Then, through a series of mergers, acquisitions, and divestitures, Danaher now focuses primarily on manufacturing scientific instruments and consumables in the life sciences and diagnostic industries after the late 2023 divestiture of its environmental and applied solutions group, Veralto.
Last trade$226.46
Day change-$3.45 (-1.50%)
Day range$225.18 – $230.83
Volume2,010,821
Market cap$161.75B
OpenXNYS
Fundamentals
Key company ratios and reported financial statements.
Source: Massive.com
Key ratios
Valuation
Market capitalization
$161.75B
Price / earnings
37.35×
Price / book
3.02×
Price / sales
6.32×
EV / sales
7.13×
EV / EBITDA
23.26×
Profitability
Earnings per share
$6.16
Return on assets
4.64%
Return on equity
8.08%
Dividend yield
0.63%
Liquidity and leverage
Debt / equity
0.49×
Current ratio
1.63×
Quick ratio
1.29×
Cash ratio
0.63×
Cash flow
Price / cash flow
23.58×
Price / free cash flow
28.24×
Free cash flow
$5.73B
Ratios use trailing-twelve-month financials and market data as of
Nov 16, 2026.
Financial statements
Income and cash flow amounts are for the period; balance sheets are point-in-time
snapshots. Amounts are shown in USD. Latest 8 quarterly or 5 annual periods are
displayed when available.
Income statement for DHR, quarterly periods
Line item
Q3 FY2026 Sep 25, 2026
Q2 FY2026 Jun 26, 2026
Q1 FY2026 Mar 27, 2026
Q4 FY2025 Dec 31, 2025
Q3 FY2025 Sep 26, 2025
Q2 FY2025 Jun 27, 2025
Q1 FY2025 Mar 28, 2025
Q4 FY2024 Dec 31, 2024
Revenue
$6.55B
$6.27B
$5.95B
$6.84B
$6.05B
$5.94B
$5.74B
$6.54B
Cost of revenue
$2.72B
$2.65B
$2.36B
$2.87B
$2.53B
$2.41B
$2.23B
$2.65B
Gross profit
$3.84B
$3.61B
$3.59B
$3.97B
$3.52B
$3.52B
$3.51B
$3.89B
Selling, general and administrative
$2.16B
$2.07B
$1.86B
$2.03B
$1.99B
$2.36B
$1.86B
$2.02B
Research and development
$433M
$412M
$387M
$438M
$378M
$403M
$379M
$442M
Total operating expenses
$2.59B
$2.48B
$2.25B
$2.46B
$2.37B
$2.76B
$2.24B
$2.47B
Operating income
$1.25B
$1.13B
$1.34B
$1.5B
$1.15B
$760M
$1.27B
$1.43B
Interest expense
-$135M
-$107M
-$63M
-$55M
-$67M
-$71M
-$72M
-$61M
Income before taxes
$1.13B
$1.08B
$1.24B
$1.37B
$1.08B
$655M
$1.13B
$1.32B
Income taxes
-$75M
$208M
$206M
$190M
$168M
$100M
$175M
$229M
Net income
$1.24B
$870M
$1.03B
$1.2B
$908M
$555M
$954M
$1.09B
Net income attributable to common shareholders
$1.24B
$870M
$1.03B
$1.2B
$908M
$555M
$954M
$1.09B
EBITDA
$1.97B
$1.79B
$1.97B
$2.13B
$1.78B
$1.37B
$1.87B
$2.05B
Basic earnings per share
$1.75
$1.23
$1.45
$1.69
$1.28
$0.77
$1.33
$1.50
Diluted earnings per share
$1.75
$1.23
$1.45
$1.68
$1.27
$0.77
$1.32
$1.49
Recent news
Company coverage with links to the original publishers.
A comparison of two Medical Services stocks reveals that Viatris (VTRS) presents a better value opportunity than Danaher (DHR). VTRS has a Zacks Rank of #2 (Buy) with improving earnings outlook and superior valuation metrics, including a forward P/E of 7.98 versus DHR's 27.39, and a Value grade of A compared to DHR's C.
Zacks analysts published research on 16 major stocks and 2 microcap stocks. Tesla faces valuation concerns despite strong software prospects. Netflix cut advertising outlook but maintains balanced investment case. American Express shows resilience with strong earnings. Microcap stocks InterGroup and Moving iMage Technologies face operational challenges but show some positive developments.
Danaher (DHR) has been upgraded to a Zacks Rank #2 (Buy) rating, reflecting upward trends in earnings estimates. The industrial and medical device maker's consensus estimate for fiscal year 2026 shows a 0.8% increase over the past three months. The upgrade positions Danaher in the top 20% of Zacks-covered stocks, suggesting potential for near-term stock price appreciation driven by improving business fundamentals.
In a comparison of two Medical Services stocks, Labcorp Holdings (LH) and Danaher (DHR), both holding a Zacks Rank #2 (Buy), Labcorp emerges as the superior value option. LH has a forward P/E of 17.67 and PEG ratio of 1.85, compared to DHR's 27.42 and 2.94 respectively. LH received a Value grade of B versus DHR's C grade, making it more attractive to value investors.
Several major companies exceeded third-quarter 2026 earnings expectations, driving positive stock movements. Capital One Financial surpassed estimates with $6.69 EPS, Bank OZK beat forecasts with $1.50 EPS, Thermo Fisher Scientific exceeded expectations with $6.68 EPS, and Danaher Corp. outperformed with $2.11 EPS.
Dividends
Declared distributions and recorded event dates. Forecasts are not
shown.
Updated daily
No declared upcoming dividend found.
Ex-dividend
Amount / share
Pay date
Type
Sep 30, 2026
$0.40
Oct 30, 2026
recurring
Jun 26, 2026
$0.40
Jul 31, 2026
recurring
Mar 27, 2026
$0.40
Apr 24, 2026
recurring
Dec 26, 2025
$0.32
Jan 30, 2026
recurring
Sep 26, 2025
$0.32
Oct 31, 2025
recurring
Stock splits
Historical share-structure events and their execution dates.